bpc 157 pdf PDF) Multifunctionality and Possible Medical Application of the Peptide—Literature and Patent Review BPC-157 - 10mg - Peplogix

Ozempic is for managing type 2 diabetes, and Wegovy is for chronic weight management

Real-world dosing and outcomes 6-month persister loss about 12-13% (Hankosky), broad-cohort about -9.8% (Adamidis), telehealth completers near -23% (Duncan)

Remove the cap from the needle and push the needle through the rubber stopper at the top of the vial

If you're compounding, you're not supposed to market direct to consumers like Big Pharma does

Adding cagrilintide to tirzepatide Theoretical protocol (not clinically studied): If on tirzepatide 10-15mg: Stable on tirzepatide for 4+ weeks Continue tirzepatide at current dose Add cagrilintide 0.6mg weekly Standard cagrilintide titration to 2.4mg Rationale: Tirzepatide is dual GIP/GLP-1 (very powerful alone) Adding amylin pathway could theoretically enhance No clinical data on this combination Uncertain if additional benefit over tirzepatide alone Concerns: GI side effects may be severe (both slow gastric emptying) Tirzepatide already produces 15-22% weight loss alone Unclear if cagrilintide adds meaningful benefit Expensive combination Verdict: Wait for clinical data